Exploring regional variation in antipsychotic coprescribing practice: A Danish questionnaire survey

Journal of Clinical Psychiatry

Volumn 71, Issue 11, 2010, Pages 1457-1464

  Baandrup, Lone ^a   Allerup, Peter ^b   Nordentoft, Merete ^a   Lublin, Henrik ^a   Glenthoj, Birte Y ^a  

^a Mental Health Center Glostrup   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; AWARENESS; CROSS-SECTIONAL STUDY; DENMARK; EDUCATION PROGRAM; ENVIRONMENT; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; NURSE ATTITUDE; OBSERVATIONAL STUDY; PHYSICIAN ATTITUDE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; WORKLOAD;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; DENMARK; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NURSES; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; QUESTIONNAIRES; SCHIZOPHRENIA;

EID: 78649792165     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05270yel     Document Type: Article

References (49)

1. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs. 1999;12(3):179-188. (Pubitemid 29446503)
2. Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv. 2003;54(8):1086.
3. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002;28(1):75-84.
4. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377-1388.
5. Paton C, Lelliott P, Harrington M, et al. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol. 2003;17(2):223-229.
6. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457.
7. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106(5):323-330. (Pubitemid 35176874)
8. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;27(2):198-204.
9. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004;11(3):313-327.
10. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52(1):503-517.
11. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002;63(2):93-94.
12. Lelliott P, Paton C, Harrington M, et al. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull. 2002;26(11):411-414. (Pubitemid 35331237)
13. Barbui C, Biancosino B, Esposito E, et al. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2007;22(4):221-225.
14. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700-706. (Pubitemid 38445515)
15. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv. 2001;52(8):1033-1036.
16. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull. 2002;28(1):105-109.
17. Loosbrock DL, Zhao Z, Johnstone BM, et al. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ. 2003;6(2):67-75.
18. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv. 2007;58(7):1007-1010.
19. National Institute for Health and Clinical Excellence (NICE). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London, England: The National Institute for Health and Clinical Excellence; 2002.
20. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th ed. London, England: Informa Healthcare; 2007.
21. Falkai P, Wobrock T, Lieberman J, et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry. 2006;7(1):5-40.
22. The International Psychopharmacology Algorithm Project (IPAP). The IPAP Schizophrenia Algorithm. www.ipap.org. Accessed 2007.
23. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60(10):649-657. (Pubitemid 29503644)
24. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597-1600.
25. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54(1):55-59.
26. Kreyenbuhl J, Marcus SC, West JC, et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv. 2007;58(7):983-990.
27. Bitter I, Chou JC, Ungvari GS, et al. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry. 2003;36(4):143-149.
28. Janssen B, Weinmann S, Berger M, et al. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull. 2004; 30(4):1023-1033. (Pubitemid 40469534)
29. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry. 1987;150(4):501-504.
30. Drake R, Skinner J, Goldman HH. What explains the diffusion of treatments for mental illness? Am J Psychiatry. 2008;165(11):1385-1392.
31. Benson PR. Factors associated with antipsychotic drug prescribing by southern psychiatrists. Med Care. 1983;21(6):639-654.
32. Hemminki E. Review of literature on the factors affecting drug prescribing. Soc Sci Med. 1975;9(2):111-116.
33. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? a framework for improvement. JAMA. 1999; 282(15):1458-1465.
34. Analysis of the psychiatric specialty: differences and similarities in the region [in Danish]. The Capital Region. Report from the Psychiatric and Social Subcommittee; 2007.
35. Statistics Denmark. www.statbank.dk. Accessed autumn 2007.
36. Leung W-C. How to design a questionnaire. Student BMJ. 2001;9:187-189.
37. Boynton PM. Administering, analysing, and reporting your questionnaire. BMJ. 2004;328(7452):1372-1375.
38. Boynton PM, Greenhalgh T. Selecting, designing, and developing your questionnaire. BMJ. 2004;328(7451):1312-1315.
39. Burgess TF. A General Introduction to the Design of Questionnaires for Survey Research, Edition 1.1; Leeds, United Kingdom: University of Leeds; 2001.
40. Koyama A, Ito H, Nakanishi M, et al. Addition of antipsychotics to medication regimens during schizophrenic inpatient care. Psychiatry Clin Neurosci. 2008;62(1):56-64.
41. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005;187(3):243-247.
42. Willis GB. Cognitive Interviewing. A "How To" Guide. Reducing Survey Error through Research on the Cognitive and Decision Processes in Surveys. Short course presented at the 1999 Meeting of the American Statistical Association. Research Triangle Institute; 1999.
43. Lwanga SK, Lemeshow S. Sample Size Determination in Health Studies: A Practical Manual. Geneva, Switzerland: WHO; 1991.
44. Proportion of occupied beds [in Danish]. http://www.sst.dk/ Indberetning%20og%20statistik/Landspatientregisteret/Belaegningsprocenter.aspx. Accessed February 2009.
45. Bjerrum L, Søgaard J, Hallas J, et al. Polypharmacy in general practice: differences between practitioners. Br J Gen Pract. 1999;49(440):195-198. (Pubitemid 29119093)
46. Johnson DAW, Wright NF. Drug prescribing for schizophrenic outpatients on depot injections: repeat surveys over 18 years. Br J Psychiatry. 1990;156(6):827-834.
47. Biancosino B, Barbui C, Marmai L, et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2005;20(6):305-309.
48. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007;58(4):489-495.
49. Sim K, Su A, Chan YH, et al. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci. 2004;58(3):324-329.